BIIB – biogen inc. (US:NASDAQ)
Stock Stats
News
1/30
08:14 am
biib
Low
Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
1/28
09:07 am
biib
Low
Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus [Yahoo! Finance]
1/28
07:30 am
biib
Low
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
1/27
07:19 am
biib
Low
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
1/25
06:42 pm
biib
Low
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review [Yahoo! Finance]
10/31/2025
04:02 pm
biib
-1.8%
BEAT
10/30/2025
04:03 pm
biib
3.1%
BEAT
10/30/2025
06:17 am
biib
4.3%
BEAT
7/31/2025
04:01 pm
biib
3.1%
BEAT
1/30
11:18 am
Maintains
Outperform
Outperform
Oppenheimer
Low
1.9%
1/30
11:18 am
Maintains
Outperform
Outperform
Oppenheimer
Low
1.9%
1/30
08:14 am
Reiterates
Outperform
Outperform
Oppenheimer Holdings, Inc.
Low
1.8%
1/27
09:48 am
Maintains
Neutral
Neutral
Citigroup
Low
0.5%
1/27
09:48 am
Maintains
Neutral
Neutral
Citigroup
Low
0.5%
1/14
06:00 am
biib
Medium
Form 8-K BIOGEN INC. For: Jan 13
12/3
04:43 pm
biib
Low
Form 4 BIOGEN INC. For: Dec 01 Filed by: Viehbacher Christopher
11/13
08:28 pm
biib
Low
Form SCHEDULE 13G/A BIOGEN INC. Filed by: PRIMECAP MANAGEMENT CO/CA/
11/10
08:15 am
biib
Low
Form SCHEDULE 13G BIOGEN INC. Filed by: STATE STREET CORP
11/4
04:13 pm
biib
Low
Form 4 BIOGEN INC. For: Oct 31 Filed by: Grogan Jane
Show more
Top News Gainers
10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
Top News Decliners
10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3